Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IV superiority study of NBP in high-risk non-disabling ischemic cerebrovascular disease
ChiCTR-IPR-17012622Phase 4Not yet recruiting
- Sponsor
- The Affiliated Hospital of Guangdong Medical University
- Start
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of butylphthalide in Ischaemic cerebral disease, transient ischaemic attack (TIA) and ischemic stroke (2 arms), sponsored by The Affiliated Hospital of Guangdong Medical University. Primary endpoint: Total effective rate of treatment. Planned start Oct 2017; status: not yet recruiting.
02
Drugs
butylphthalide
03
Conditions
Ischaemic cerebral diseasetransient ischaemic attack (TIA)ischemic stroke
Beyond the preview
Go deeper on ChiCTR-IPR-17012622.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-17012622.